Cyber Security for Regulated Pharmaceutical & Life Science Organisations
Protecting clinical trials, manufacturing data, and regulatory approval, not just IT systems.
The Reality
Regulators do not ask whether you were attacked.
They ask whether your data can still be trusted.
In pharmaceutical manufacturing and clinical research, data integrity is everything.
A single cybersecurity failure can:
Invalidate clinical trial data
Trigger regulatory findings
Delay or halt approvals
Force re-validation or re-trials
Expose patient data and intellectual property.
CyberGXP was created to address one core risk:
Loss of regulatory confidence due to compromised data integrity.
The
Pharmaceutical Lifecycle
From early research to post-approval manufacturing, cyber risk follows your product. At every stage, compromised systems can lead to questioned data and delayed outcomes.
Select your current clinical or manufacturing stage to see the cyber risks, regulatory expectations, and protections relevant to you.
Pre-Clinical
Research Data
Pre-clinical research is where pharmaceutical and healthcare innovation begins, and where some of the most valuable and vulnerable data is created.
Clinical Trials
(Phase I–III)
Clinical trials introduce a significant increase in cyber risk as organisations begin handling sensitive patient data, trial protocols, and multi-party collaboration across sponsors, CROs, and research sites.
Regulatory Submissions
Regulatory submissions represent a critical point where data integrity, traceability, and compliance are under intense scrutiny.
GMP Manufacturing Systems
GMP manufacturing environments rely on complex, interconnected systems that directly impact product quality and patient safety.
Post-Approval Operations & Inspections
Following approval, organisations enter a phase of ongoing regulatory oversight where systems, data, and processes remain subject to inspection and audit.
Cyber Security designed for regulated pharmaceutical environments.
Because your approval depends on it.